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ABSTRACT
Previous studies proven that cochlear hair cells’ death plays an important 
role in sensorineural hearing loss due to radiation exposure. Other studies 
compared the differences between the impact of conventional radiotherapy 
(CRT) and intensity modulated radiation therapy (IMRT) on hearing loss in 
patients with nasopharyngeal carcinoma. Although, few differences found 
in some clinical manifestation, however no statistical analysis had been 
carried out. The aim of study was to evaluate the risk of sensory hearing loss 
in nasopharyngeal carcinoma patients who received CRT compared to IMRT. 
A case control study was performed on nasopharyngeal carcinoma patients 
who received radiotherapy at Dr. Sardjito General Hospital, Yogyakarta. 
The result of DPOAE between NPC patients who received CRT and IMRT was 
compared in this study. Statistical analysis was performed using chi square 
test and multivariate analysis. The result showed that patients who received 
CRT significantly altered the risk for sensory hearing loss in the contralateral 
ear as much as 11.2 times according to the multivariate analysis (CI 95%: 2.2 – 
56.6; p=0.004). In conclusion, the risk of sensory hearing loss in patients with 
nasopharyngeal carcinoma who received CRT is a greater compared to IMRT.
ABSTRAK
Penelitian sebelumnya membuktikan bahwa kematian sel rambut koklea 
berperan penting dalam terjadinya gangguan pendengaran sensorineural 
akibat paparan radiasi. Penelitian yang membandingkan paparan radioterapi 
konvensional (CRT) dengan intensity modulated radiation therapy (IMRT) 
terhadap gangguan pendengaran pada pasien karsinoma nasofaring 
menunjukkan adanya perbedaan pada beberapa manifestasi klinis, walaupun 
analisis statistiknya tidak dilakukan. Tujuan penelitian ini adalah mengevaluasi 
risiko gangguan pendengaran sensoris pasien karsinoma nasofaring yang 
mendapat CRT dibandingkan dengan IMRT. Penelitian dengan rancangan 
potong lintang ini dilakukan pada pasien karsinoma nasofaring yang 
mendapatkan radioterapi di RSUP Dr. Sardjito, Yogyakarta. Hasil DPOAE antara 
pasien KNF yang mendapat CRT dan IMRT dibandingkan dalam penelitian ini. 
Analisis statistik dilakukan dengan menggunakan uji chi square dan analisis 
multivariat. Hasil penelitian menunjukkan bahwa pasien yang menerima 
CRT secara signifikan meningkatkan risiko gangguan pendengaran sensoris 
di telinga kontralateral sebanyak 11,2 kali pada analisis multivariat (CI 95%: 
2,2 – 56,6; p=0,004). Dapat disimpulkan bahwa risiko gangguan pendengaran 
sensoris di telinga kontralateral dari sisi tumor pasien yang menerima CRT 
lebih tinggi dibandingkan IMRT.
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INTRODUCTION
Radiotherapy is a notable component 
in the treatment of cancer, especially in 
head and neck cancer that can evoke the 
risk of ototoxicity from the radiation. 
It has also known as radiation induced 
sensorineural hearing loss/RISNHL. The 
induction could be happened when the 
inner ear was exposed to the radiation 
field. About one third of head and neck 
cancer patients who had undergone 
radiotherapy having a side effect such as 
ototoxicity.1 The ototoxicity is defined as 
a cellular degeneration within cochlear 
tissue and/or vestibular organ that cause 
functional changes of the use of some 
application therapeutic agent.2 There 
were several factors that contributed 
to the event of hearing problem in post 
radiation patients including radiation 
dosage, technique administration of 
adjuvant chemotherapy, and patient’s 
age.3,4
It was reported that radiation 
exposure could lead to the demise of 
cochlear hair cells. It would be impact 
to sensory hearing loss clinically. The 
radiation has few side effects on the cell 
by damaging a chemical bond within 
cellular basic component of structure 
such as fat, protein, and the most 
important genetic component of cells 
that was a DNA. Generally, cell death is 
an immensely heterogenic process that 
could be happened during a pathway of 
cellular cycle including the process of 
apoptosis, necrosis, and mitosis.1,5  
Nilakhe et al.6 reported that patients 
with head and neck cancer who 
received radiotherapy would encounter 
a conductive and/or sensory neural 
hearing loss with the peak incidence 
was significantly higher at 6th months 
after radiotherapy. However, only 
12% NPC was involved in this study, 
where laryngeal cancer was 24%. The 
conclusion of this study became more 
challenging due to the different dosage 
of radiation received on the mass of 
NPC and the mass of laryngeal cancer. 
The ear would be more exposed by 
radiation in NPCs’group than Laryngeal 
cancer’s group. In addition, Gabriele et 
al.7 demonstrated that the total radiation 
dose is related to vestibular disorder 
slightly.
Ondrey et al.8 studied the amount 
of radiation dosage received by cochlea 
in a few cases of head and neck cancer. 
The result showed that patients who 
received radiotherapy using external 
beam radiation therapy (EBRT) with 
fractionation, only 100 Gray from the 
total of 7,020 Gray, could seize the cochlea 
in laryngeal cancer patients.  Singh et 
al.9 and Chen et al.10 reported that BERA 
result in post radiation sensorineural 
hearing lost in head and neck cancer 
patients showed the representation 
of cochlear abnormalities without 
impact in retrocochlear part. Honore 
et al.11 reported a relationship between 
radiation dosage received by cochlea 
with the incidence of sensory neural 
hearing loss in nasopharyngeal cancer’s 
patients after radiotherapy. An uplift 
of dosage to the cochlea by receiving 
initial radiotherapy could escalate the 
risk of sensory neural hearing loss. 
The aim of the study was to investigate 
the risk of sensory hearing loss in 
nasopharyngeal carcinoma patient who 
received conventional radiotherapy 




It was a case control study conducted 
in Dr. Sardjito General Hospital, 
Yogyakarta involving nasopharyngeal 
patients who underwent external 
radiotherapy. The data was collected 
from March 2nd to March 20th, 2020 at the 
Department of Radiotherapy, Dr. Sardjito 
General Hospital, Yogyakarta.
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Protocol of study
Protocol of the study has been 
approved by the Medical and Health 
Research Ethic Committee, the Faculty 
of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada/Dr. Sardjito 
General Hospital (KE/FK/0200/EC/2020). 
Distortion product otoacoustice mission 
(DPOAE) examination was performed 
to each patient at the ear contralateral 
to the site of the nasopharyngeal 
tumor. Otoscopic and tympanometry 
examinations were carried out 
with the normal results in the outer 
and middle ear. The diagnose of 
nasopharyngeal carcinoma was based 
on histopathologic examination from 
biopsy of nasopharyngeal mass, and CT 
scan contributed to determine tumor 
margins. The function of outer hair cell 
was examined by DPOAE that the results 
were that “pass” was referring normal 
function of outer hair cell and “refer” 
was referring defect in the outer hair 
cell. The research sample was defined as 
all nasopharyngeal cancer patients who 
underwent radiotherapy at Dr. Sardjito 
General Hospital, Yogyakarta from 
one to three years before the DPOAE 
examination that fulfilled the inclusion 
and exclusion criteria.
The inclusion criteria of the study 
were nasopharyngeal carcinoma patients 
who underwent external radiotherapy 
with or without chemotherapy 
between one to three years in advance, 
normal otoscopic examination, the 
tympanometry showed type A, and the 
mass of nasopharyngeal carcinoma was 
limited to one side of the nasopharynx, 
not exceeding the midline. The exclusion 
criteria were patients who had history 
of radiotherapy or chemotherapy prior 
to the series of therapy and patients who 
have previous history of using muscular 
drugs.
Statistical analysis
A chi squared test was applied for 
the statistical analysis of this study as 
well as Fischer exact test if the data 
distribution was not compatible for 
chi square test. The data analyzed was 
categorized into two groups, case and 
control based on DPOAE results. The 
case group consisted of patients with 
“refer” DPOAE results, and the control 
group consisted of patients with “pass” 
DPOAE results. Both intervention of 
conventional radiotherapy (CRT) and 
intensity-modulated radiation therapy 
(IMRT) was classified into case and 
control group.
The significant value was set at 
p < 0.05, the calculation of odds ratio 
(OR) and confidence interval (CI) of 
95% to assess the enormity of the risk 
factors. Analysis of characteristics of the 
subjects such as age, gender, history of 
chemotherapy, and interval between 
radiotherapy and DPOAE examination 
(radiotherapy-testing interval) was also 
performed. If there were some variables 
that was not homogenous, it would be 
terminated in the multivariate analysis.
RESULTS
The data obtained from the study 
was analyzed based on its characteristic 
and the results of DPOAE. There were 
40 subjects that met the inclusion and 
exclusion criteria, the subjects were 
divided into case and control groups 
(TABLE 1). Analysis of radiotherapy 
techniques on the results of DPOAE in 
the earcontralateral from the side of the 
tumor was shown in TABLE 2. There was 
difference between NPC patients who 
received CRT compared to IMRT with 
odd ratio was 9,333 (p=0.004).
Multivariate analysis using 
logistic regression was carried out to 
demonstrate all variables as shown in 
TABLE 3. The results showed that only 
type of radiotherapy was statistically 
significant to the results of DPOAE 
(p=0.004).  Other factors such as age, 
gender, history of chemotherapy, and 
radiotherapy-testing interval were not 
statistically significant (p> 0.05).
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TABLE 1. Characteristics of subjects
Characteristics Refer (%) Pass (%) Total (%) p
Age* 
•	≥60 y.o. 5 (12.5) 4 (10) 9 (22.5)
1.000
•	<60 y.o. 15 (37.5) 16 (40) 31 (77.5)
Gender**
•	Male 13 (32.5) 10 (25) 23 (57.5)
0.522
•	Female 7 (17.5) 10 (25) 17 (42.5)
History of chemotherapy*
•	Yes 17 (42.5) 18 (45) 35 (87.5)
1.000
•	No 3 (7.5) 2 (5) 5 (12.5)
Radiotherapy-Testing Interval**
•	2 to ≤ 3 years 7 (17.5) 7 (17.5) 14 (35)
1.000
•	1 to <2 years 13 (32.5) 13 (32.5) 26 (65)
*Fisher or **X2 test result was considered significant if p<0.05
TABLE 2. Analysis of radiotherapy techniques on the results of DPOAE in the ear 
contralateral from the side of the tumor
R a d i o t h e r a p y 
techniques
Refer (%) Pass (%) Total (%) OR p
CRT 16 (40.0) 6 (15.0) 22 (55.0) 1
0.004
IMRT 4 (10.0) 14 (35.0) 18 (45.0) 9,333*(2,180-39,962)
*X2-test result was considered significant if p<0.05
 
TABLE 3. Analysis of variables related to the results of DPOAE in the ear iscontralateral 
from the tumor side
Variable
Univariate analysis Multivariate analysis
Total OR (95% CI) p OR (95% CI) p 
Group of Age
•	≥60 years old 9 1
1.333 (0.338-7.725)
1.000 1.686 (0.267- 10.636) 0.578









1.000 0.248 (0.017- 3.603) 0.307
•	No 5
Radiotherapy-testing interval
•	2 to ≤ 3 years 14 1
1.000 (0.370- 5.028)
1.000 1.377 (0.269- 7.058) 0.701




0.004* 11.186 (2.211- 56.597) 0.004**
•	 IMRT 18
*The result was considered significant if p<0.05 in univariate analysis
**The result was considered significant if p<0.05 in multivariate analysis
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Age group ≥ 60 y.o., male gender, 
and radiotherapy-testing interval 2 to ≤ 3 
years each increased the risk of sensory 
hearing loss in the contralateral ears by 
1.7 times (CI 95%: 0.27-10.10), 3.7 times (CI 
95%: 0.62-22.57), and 1.4 times (CI 95%: 
0.27-7.06) respectively. However, they 
were not significant (p>0.05). History of 
chemotherapy also was not significantly 
lowering the risk of sensory hearing loss 
in the contralateral ear by 0.25 times 
(CI 95%: 0.02-3.6; p=0.307). It might 
become a problem, because the number 
of nasopharyngeal carcinoma patients 
who did not undergo chemotherapy was 
very small. The technique of CRT was 
statistically significant in order to alter 
the risk of sensory hearing loss in the 
contralateral ear by 11.2 times (CI 95%: 
2.21- 56.6; p=0.004).
DISCUSSION
There were significantly different 
of DPOAE between case and control 
group both in CRT and IMRT (OR= 9,333; 
p=0.04). It indicated that the CRT had 
higher risk of outer hair cells damage 
in the ear contralateral to the side of 
nasopharyngeal carcinoma tumor 
compared to IMRT. The difference 
in DPOAE results could be caused by 
several factors like cochlear dosage 
to the contralateral side. It had been 
known that the delineation method in 
IMRT was better than CRT technique. 
El-Ghoneimy et al.12 compared the 
impact of the technique used with the 
dosage of radiation to the cochlea in the 
nasopharyngeal carcinoma patients. 
The results showed that IMRT has lower 
cochlear dosage significantly than CRT 
with 7 Gray lower. In addition, the study 
demonstrated that the total dosage was 
around 70 Gray divided into 33 fractions. 
This study correlated with other study in 
the total dosage given, 70 Gray divided 
into 30 – 35 fractions, was depending 
on the therapeutic response from each 
patient. This dosage distribution by 
fractions was known as conventional 
fractionation method.
This type of fractionation method 
was not taken into an account as one of 
the contributing factors in this research 
because all of external radiation in 
our institution used conventional 
fractionation method by dividing 
three total dosage of 70 Gray into 30-
35 fractions within the period of 6 to 
7 weeks. It was given 5 fractions per 
week with every fraction per day. This 
procedure disclosed that the patient 
would receive 2.2 Gray each day.
Lannering et al.13 reported that the 
use of conventional fractionation method 
would reduce the cochlear dosage rather 
than the use of hyper fractionation 
method in medul loblastoma cases, 
because the dosage was given 10 
Gray greater than conventional. This 
additional cochlear dosage would 
increase the risk of cochlear outer hair 
cell damage that could be observed in 
DPOAE’s results. Chen et al.10 repored that 
nasopharyngeal patients who received 
3D conventional radiotherapy technique 
would be exposed with higher radiation 
dosage of 35.5 Gray to the cochlea from 
the total dosage of 65-70 Gray that was 
given within the period of 6-8 weeks. 
The DPOAE results showed significant 
difference at one year before and after 
radiotherapy.
Nurmasari et al.14 observed the 
shorter interval of radiotherapy in the 
DPOAE examination. It was discovered 
that there was no statistically significant 
difference in DPOAE results before and 
after the administration of 20 Gray 
dosage. However, after the administered 
of the total dosage reached 40 Gray, 
significantly different in statistic began 
to be obtained before and after therapy. 
The difference stayed significant even 
until one month after receiving final 
total dosage of 66 Gray, but there was 
no statistically significant difference 
between shortly after final dosage and 
one month after latter dosage. Patients 
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with middle ear abnormality confirmed 
with tympanometry were excluded from 
the data calculation. The technique used 
for the radiotherapy was not mentioned, 
but considering the timing and date of 
the data collection, the technique used 
in the study was probably conventional 
radiotherapy.
In this study, the interval between 
radiotherapy and DPOAE examination 
was be appointed at one to three years. 
This interval was chosen based on two 
previous studies by Nilakhe et al.6 and 
Hwang et al.3 who showed that the 
incidence of sensorineural hearing loss 
was begun to be detected 6 months after 
the radiotherapy, and would be altered 
in the upcoming years, even after 9 
years alongside from the patient’s age. 
Another reason was that the modality 
of radiotherapy in one to three years 
before the data collection was in the 
process of transitioning from CRT to 
IMRT. Therefore it was expected that the 
retrospective samples hopefully could 
attain a sufficient proportion.
Petsuksiri et al.15 compared the 
difference between the technique of 
radiation therapy specifically CRT and 
IMRT involving  68 patients with NPC. 
The incidence of SNHL in 4000 Hz 
frequency were 48.75% in CRT groups 
and 37% in IMRT groups. However, it 
was not statistical analysis performed of 
the data obtained from research results. 
Therefore, it was difficult to conclude the 
different effects of each technique to the 
incidence of the sensorineural hearing 
loss. This study was resembling to our 
study, but the difference was that our 
study specifically examined the outer 
hair cell (sensory hearing loss) with 
DPOAE.
Recently, there are no studies to 
corelate the damage of outer hair cells in 
the ear contralateral from the side of the 
tumor. Most of the previous studies did 
not separate the side of the tumor with 
the side of the ear studied. This study will 
provide a new overview in whether the 
contralateral ear can still be maintained 
if the IMRT radiotherapy techniques was 
chosen side from to CRT. The use of IMRT 
provides a protection factor to outer hair 
cells by 11 times better than those that 
use CRT, indicating that the application 
of IMRT can be considered in preserving 
the hearing function of the contralateral 
ear.
This study realized the limitations 
compared to previous studies including 
the lack of control of the factors that 
affect the contralateral ear. In addition, 
the confidence interval of OR value for 
the type of radiotherapy is still quite 
wide.
CONCLUSION
There is a greater risk of 
sensory hearing loss in patients with 
nasopharyngeal carcinoma who 
received CRT compared to IMRT. Based 
on multivariate analysis, the results of 
DPOAE in the group of contralateral ears 
who received CRT with “refer” results 
are 11 times higher than IMRT’s group, 
and 9 times higher based on bivariate 
analysis.
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